The purpose of this Phase 1, multicenter, open-label study was to determine the maximum tolerated dose (MTD) of AG-636 and characterize its dose-limiting toxicities (DLTs) when given by mouth to subjects with advanced lymphoma that is refractory to standard treatment. During the dose-escalation part of the study successive cohorts of subjects will be treated with increasing doses of AG-636 in order to determine its maximum tolerated dose (MTD). Subsequently, in the dose-expansion part of the study, additional subjects will be treated at the MTD in order to confirm that dose's safety, tolerability, PK and PD, and to provide an opportunity to detect anti-lymphoma activity. The dose expansion part of the study will support the selection of a dose for future clinical studies (a recommended Phase 2 dose [RP2D]).
Yiwen Cao et.al. conducted a study to investigate the clinical relevance of B‐vitamins and single nucleotide polymorphisms on One‐carbon metabolism ‐related genes in diffuse large B‐cell lymphoma. The researchers concluded that alterations in B‐vitamin metabolism significantly affected disease progression and had a prognostic impact on diffuse large B‐cell lymphoma.
Androgen-deprivation therapy (ADT) with an oral gonadotropin-releasing hormone (GnRH) antagonist rapidly suppressed testosterone and cut the incidence of serious heart events compared to an injectable form of ADT, a phase III trial found. The so-called HERO study of over 900 patients met its primary endpoint, demonstrating that castration at 48 weeks was maintained in 96.7% of those assigned to oral relugolix compared to 88.8% of those on leuprolide injection, meeting prespecified criteria for both non-inferiority and superiority (P<0.001), reported Neal Shore, MD, of the Carolina Urologic Research Center in Myrtle Beach, South Carolina.
Frontline pembrolizumab doubled progression-free survival (PFS), when compared with chemotherapy, among patients with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer in the KEYNOTE-177 study. The median PFS was 16.5 months for patients who received pembrolizumab and 8.2 months for those who received investigators' choice of chemotherapy (one of six regimens).
Some women with gestational trophoblastic tumors (GTT), a rare type of cancer that develops in the placenta during pregnancy, respond to immunotherapy when they are resistant to single chemotherapy, French researchers report. The finding comes from the TROPHIMMUN phase 2 trial with the anti-programmed death-ligand 1 (PD-L1) drug avelumab (Bavencio, Merck/Pfizer). The study will be presented at the plenary session of the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting, held virtually because of the pandemic. A glimpse of the results was given at a pre-meeting press cast by lead author Benoit You, MD, Ph.D., Lyon Investigational Center for Treatments in Oncology and Hematology, France.
For men with advanced prostate cancer, the oral gonadotropin-releasing hormone (GnRH) antagonist relugolix maintains testosterone suppression compared with the GnRH agonist leuprolide, while enzalutamide is associated with improved survival versus placebo in nonmetastatic, castration-resistant prostate cancer, according to two studies published online May 29 in the New England Journal of Medicine to coincide with the American Society of Clinical Oncology Virtual Scientific Program. Neal D. Shore, M.D. et al randomly assigned patients with advanced prostate cancer to receive relugolix (orally once daily) or leuprolide (injections every three months) for 48 weeks (622 and 308 patients, respectively). The researchers found that 96.7 and 88.8 percent of men receiving relugolix or leuprolide, respectively, maintained castration (sustained testosterone suppression to castrate levels) through 48 weeks. The difference indicated the noninferiority and superiority of relugolix. The superiority of relugolix over leuprolide was also demonstrated in all other key secondary endpoints.
Genetic screening for prostate cancer in GP surgeries could be effective at picking up otherwise undiagnosed cases of the disease, a new pilot study shows. Researchers 'barcoded' men for their genetic risk of prostate cancer by testing each for 130 DNA changes—and gave those at higher risk follow-up checks. Their study found that population screening was safe and feasible, and identified new prostate cancers in over a third of apparently healthy men who were found to have the highest levels of inherited risk.
The purpose of this study is to find the most effective dose of radiation therapy to give to breast tumors in a shorter period of time, prior to standard partial mastectomy/axillary surgery.
This research study is being done to understand how patients with chronic cancer pain take their long-acting opioid medications and to develop an intervention to enhance cancer pain management.
Advance in Cancer Prevention addresses all types of cancer, how cancer forms in the body, and their prevention. It focuses on Cancer Vaccines, Chemotherapy, Radioactive Iodine Therapy, Breast Reconstruction Surgery, Mammography, Chemoprevention, aromatase inhibitors, Scintimammography, Oncoplastic surgery, Sumoylation, Dietary Supplements, Cancer Screening, Cancer and Nutrition, Exercise and Cancer, Alternative Cancer Medicines, Stem cell transplants for cancer prevention, Naturopathic Treatments, Clinical Naturopathy, Cancer Prevention from nuts.